Connable Office Inc. Sells 167 Shares of Amgen Inc. (AMGN)
Connable Office Inc. cut its position in Amgen Inc. (NASDAQ:AMGN) by 1.3% during the third quarter, Holdings Channel reports. The firm owned 13,043 shares of the medical research company’s stock after selling 167 shares during the period. Connable Office Inc.’s holdings in Amgen were worth $2,176,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. Bank of Montreal Can bought a new position in shares of Amgen during the second quarter worth approximately $383,036,000. FMR LLC boosted its position in shares of Amgen by 4.0% in the second quarter. FMR LLC now owns 32,386,936 shares of the medical research company’s stock worth $4,927,672,000 after buying an additional 1,259,875 shares during the period. Vanguard Group Inc. boosted its position in shares of Amgen by 1.5% in the second quarter. Vanguard Group Inc. now owns 46,679,076 shares of the medical research company’s stock worth $7,102,222,000 after buying an additional 673,247 shares during the period. Pictet Asset Management Ltd. boosted its position in shares of Amgen by 71.7% in the second quarter. Pictet Asset Management Ltd. now owns 1,460,956 shares of the medical research company’s stock worth $230,758,000 after buying an additional 610,106 shares during the period. Finally, Numeric Investors LLC boosted its position in shares of Amgen by 58.2% in the second quarter. Numeric Investors LLC now owns 1,620,496 shares of the medical research company’s stock worth $246,558,000 after buying an additional 596,160 shares during the period. Hedge funds and other institutional investors own 77.90% of the company’s stock.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at 156.12 on Friday. The stock has a market cap of $116.14 billion, a P/E ratio of 15.63 and a beta of 1.14. The stock has a 50 day moving average price of $146.78 and a 200-day moving average price of $159.07. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $176.85.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, October 27th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.79 by $0.23. The business had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.73 billion. Amgen had a return on equity of 29.27% and a net margin of 33.63%. The company’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period last year, the firm earned $2.72 earnings per share. Equities analysts predict that Amgen Inc. will post $11.55 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 8th. Shareholders of record on Wednesday, February 15th will be paid a $1.15 dividend. The ex-dividend date is Monday, February 13th. This is a boost from Amgen’s previous quarterly dividend of $1.00. This represents a $4.60 dividend on an annualized basis and a yield of 2.95%. Amgen’s dividend payout ratio (DPR) is currently 39.92%.
AMGN has been the subject of a number of recent research reports. RBC Capital Markets set a $190.00 target price on Amgen and gave the stock a “buy” rating in a report on Wednesday, January 4th. Zacks Investment Research lowered Amgen from a “hold” rating to a “sell” rating in a research note on Tuesday, January 3rd. Vetr raised Amgen from a “buy” rating to a “strong-buy” rating and set a $182.34 price target for the company in a research note on Monday, October 24th. Cowen and Company reissued a “buy” rating on shares of Amgen in a research note on Monday, September 19th. Finally, Leerink Swann reissued a “market perform” rating and set a $163.00 price target (down from $193.00) on shares of Amgen in a research note on Friday, October 28th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $179.48.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.